首页 > 市场调查报告书 > 製药

疫苗感染疾病

市场调查报告书

商品编码

1348917

疟疾疫苗市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按疫苗类型、管理途径、地区和竞争细分

Malaria Vaccine Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Vaccine Type, By Route of Administration, Region and Competition

出版日期: 2023年08月01日 | 出版商:

TechSci Research | 英文 114 Pages | 商品交期: 2-3个工作天内

价格

简介目录

全球疟疾疫苗市场在 2024-2028 年预测期内将出现令人印象深刻的成长。这可以归因于疟疾盛行率的增加、研发活动的增加以及医疗基础设施投资的增加。疟疾是许多发展中国家，特别是撒哈拉以南非洲国家的一个主要公共卫生问题。这种疾病的沉重负担产生了对有效疟疾疫苗的强烈需求。这导致了对开发可以预防疟疾感染或减轻其严重程度的疫苗的大量投资。根据最新的《世界疟疾报告》，2021 年有 2.47 亿例疟疾病例，高于 2020 年的 2.45 亿例。与 2020 年的 625,000 人相比，2021 年与疟疾相关的死亡人数预计为 619, 000 人。

生物技术的进步大大加速了疟疾疫苗的开发。近年来，人们对疟疾感染的分子和细胞机制有了更深入的了解，从而确定了潜在的候选疫苗。此外，DNA疫苗和病毒载体疫苗等疫苗开发技术的进步，使得能够创造出更有效、更安全的疟疾疫苗，为未来几年全球疟疾疫苗市场的成长开闢了新的前景。

市场概况
预测期	2024-2028
2022 年市场规模	40102万美元
2028 年市场规模	5.2919亿美元
复合年增长率	4.6%
成长最快的细分市场	前红血球
最大的市场	中东和非洲

疟疾盛行率增加

疟疾盛行率的不断上升是全球疟疾疫苗市场的主要驱动力之一。疟疾是一种危及生命的疾病，由疟原虫寄生虫引起，透过受感染的蚊子叮咬传播给人类。世界卫生组织预计，到 2021 年，全球近一半人口将面临疟疾威胁。预计 2021 年将有 619 000 人死于疟疾。世卫组织非洲区域承担了全球疟疾负担的很大一部分。 2021 年，95% 的疟疾病例和 96% 的疟疾死亡发生在该区域。在该区域，80% 的疟疾死亡病例是五岁以下儿童。疟疾的高发病率导致对开发新疗法和预防措施（包括疫苗）的投资增加。疟疾疫苗有可能成为对抗这种疾病的重要工具，特别是在其他干预措施可能效果较差的高负担地区。疟疾的日益普及也导致製药公司和非营利组织增加了研发投资。这导致了新候选疫苗的开发以及现有疫苗在新人群中的测试。

加强研究与开发

不断增加的研发（R＆D）活动是全球疟疾疫苗市场成长的关键驱动力。开发有效的疟疾疫苗对于减轻这种致命疾病的负担至关重要，特别是在疟疾最流行的低收入和中等收入国家。撒哈拉以南非洲和世界其他地区的疟疾发生率较高，导致对新疫苗开发的投资增加。许多製药公司、学术机构和非营利组织正在致力于开发新的疟疾疫苗并改进现有疫苗。全球疟疾疫苗市场的研发活动集中在几个领域，包括新疫苗标靶的确定、新型疫苗输送系统的开发以及新候选疫苗的临床试验测试。全球疟疾疫苗市场不断增加的研发活动得到了政府资金、私人投资和慈善捐赠的支持。例如，比尔和梅琳达盖兹基金会为疟疾疫苗的研发提供了大量资金，包括支持 Mosquirix 疫苗的开发。

增加投资

增加对开发和改善医疗基础设施的投资是全球疟疾疫苗市场成长的另一个重要驱动力。开发有效的疟疾疫苗只是对抗这种疾病的解决方案的一部分。同样重要的是建立强大的医疗基础设施，可以有效地向有需要的人提供疫苗。在疟疾最流行的许多低收入和中等收入国家，医疗基础设施往往不足或根本不存在，导致难以有效提供疫苗和其他基本医疗服务。增加对医疗保健基础设施的投资可以透过提高包括疫苗在内的医疗保健服务的可用性和可近性来帮助解决这个问题。这包括对医疗设施、医疗设备、医疗人员和医疗物流的投资。例如，投资建造新的医疗保健设施，如诊所和医院，可以帮助扩大服务不足地区获得医疗保健服务的机会。对冰箱和冰柜等医疗设备的投资有助于确保疫苗正确储存并保持有效性。政府和私部门资金都支持增加对医疗基础设施的投资。增加对医疗保健基础设施的投资，透过提高包括疫苗在内的医疗保健服务的可用性和可近性，正在推动全球疟疾疫苗市场的成长。

最新进展：

这种名为 R21/Matrix-M 的疟疾疫苗由印度血清研究所生产，已获得加纳政府批准在该国使用。这标誌着抗击疟疾的斗争向前迈出了重要一步，疟疾是加纳和其他撒哈拉以南非洲国家的一个主要公共卫生问题。

Mosquirix 是一种疫苗，旨在预防恶性疟原虫（最致命的疟疾寄生虫）。该疫苗由葛兰素史克 (GSK) 与 PATH 疟疾疫苗倡议合作开发，已获得欧洲药品管理局 (EMA) 批准使用。

CVac 是一种全寄生虫疟疾疫苗，利用基因改造寄生虫刺激免疫反应。 2021年，诺华宣布完成了CVac疫苗的1期临床试验，结果显示该疫苗在健康志愿者中是安全且耐受性良好的。该公司计划推进二期临床试验以评估疫苗的功效。

2021年，印度血清研究所宣布与牛津大学合作开发一种新的以mRNA为基础的疟疾疫苗。该疫苗将使用与开发 Pfizer-BioNTech 和 Moderna COVID-19 疫苗相同的技术。与传统疫苗相比，mRNA 疫苗有可能提供更有效的免疫反应。

市场区隔：

全球疟疾疫苗市场可以按疫苗类型、给药途径和地区进行细分。根据疫苗类型，全球疟疾疫苗市场可分为红血球前疫苗、红血球疫苗、多抗原疫苗和其他疫苗。根据给药途径，全球疟疾疫苗市场分为肌肉内、皮下、皮内和其他。从地区来看，疟疾疫苗市场可分为北美、欧洲、亚太地区、南美洲以及中东和非洲。

市场参与者

GlaxoSmithKline, Plc.、Novartis AG、Takeda Pharmaceutical Company、Sanaria Inc.、Merck & Co、Johnson & Johnson、Pfizer Inc.、Serum Institute of India Private Limited、Bharat Biotech International Limited、Moderna Inc 是营运中的一些领先参与者在全球疟疾疫苗市场。

报告范围：

在本报告中，除了以下详细介绍的产业趋势外，全球疟疾疫苗市场也分为以下几类：

全球疟疾疫苗市场，依疫苗类型：

前红血球

红血球

多抗原

其他的

全球疟疾疫苗市场（依给药途径）：

肌肉注射

皮下

皮内

其他的

全球疟疾疫苗市场（按地区）：

北美洲

美国

加拿大

墨西哥

欧洲

德国

英国

法国

义大利

西班牙

亚太地区

印度

日本

韩国

澳洲

越南

印尼

缅甸

南美洲

巴西

哥伦比亚

中东和非洲

南非

沙乌地阿拉伯

阿联酋

埃及

土耳其

奈及利亚

竞争格局

公司概况：全球疟疾疫苗市场主要公司的详细分析。

可用的客製化：

根据给定的市场数据，TechSci Research 可根据公司的具体需求提供客製化服务。该报告可以使用以下自订选项：

公司资讯

其他市场参与者（最多五个）的详细分析和概况分析。

Global Malaria Vaccine Market will witness an impressive growth during the forecast period, 2024-2028. This can be ascribed to the increasing prevalence of malaria, growing R&D activities and increasing investment in healthcare infrastructure. Malaria is a major public health problem in many developing countries, particularly in sub-Saharan Africa. The high burden of the disease has created a strong demand for effective malaria vaccines. This has led to significant investment in the development of vaccines that can prevent malaria infection or reduce its severity. In 2021, there were 247 million cases of malaria, up from 245 million cases in 2020, according to the most recent World Malaria Report. Compared to 625,000 in 2020, the expected number of malaria-related deaths was 619, 000 in 2021.

Advancements in biotechnology have significantly accelerated the development of malaria vaccines. In recent years, there has been a greater understanding of the molecular and cellular mechanisms involved in malaria infection, which has led to the identification of potential vaccine candidates. Additionally, advances in vaccine development technologies, such as DNA vaccines and viral vector-based vaccines, have allowed for the creation of more effective and safer malaria vaccines, thereby opening new prospects for the growth of global malaria vaccine market in the next few years.

The growth of the malaria vaccine market faces several challenges, including scientific complexities due to the complex nature of the malaria parasite and its ability to mutate rapidly, financial constraints in terms of research and development costs, regulatory hurdles for approval and distribution, limited infrastructure in some regions for effective vaccine distribution, and the growing trend of vaccine hesitancy and political instability in malaria-endemic areas. Developing a vaccine requires approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This process can be lengthy and expensive, and the requirements for approval can be stringent, making it difficult for smaller companies to navigate the process.

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 401.02 Million
Market Size 2028	USD 529.19 Million
CAGR	4.6%
Fastest Growing Segment	Pre-Erythrocytic
Largest Market	Middle East & Africa

Increasing Prevalence of Malaria

The growing prevalence of malaria is one of the key drivers of the global malaria vaccine market. Malaria is a life-threatening disease that is caused by the Plasmodium parasite, which is transmitted to humans through the bite of infected mosquitoes. Nearly half of the world's population was predicted to be in danger of malaria in 2021 by WHO. 619 000 deaths from malaria were anticipated in 2021. A disproportionately large amount of the worldwide malaria burden is placed on the WHO African Region. 95% of malaria cases and 96% of malaria deaths occurred in the Region in 2021. In the region, 80% of all malaria deaths were in children under the age of five. The high prevalence of malaria has led to increased investment in the development of new treatments and preventive measures, including vaccines. Malaria vaccines have the potential to be an important tool in the fight against the disease, particularly in high-burden areas where other interventions may be less effective. The growing prevalence of malaria has also led to increased investment in research and development by pharmaceutical companies and non-profit organizations. This has led to the development of new vaccine candidates and the testing of existing vaccines in new populations.

Increasing Research & Development

Increasing research and development (R&D) activities are a key driver of the growth of the global malaria vaccine market. The development of effective malaria vaccines is critical to reducing the burden of this deadly disease, particularly in low- and middle-income countries where malaria is most prevalent. The high incidence of malaria in sub-Saharan Africa and other parts of the world has led to increased investment in the development of new vaccines. Many pharmaceutical companies, academic institutions, and non-profit organizations are working on developing new malaria vaccines and improving existing ones. R&D activities in the global malaria vaccine market are focused on several areas, including the identification of new vaccine targets, the development of novel vaccine delivery systems, and the testing of new vaccine candidates in clinical trials. Increasing R&D activities in the global malaria vaccine market have been supported by government funding, private investment, and philanthropic donations. For instance, the Bill and Melinda Gates Foundation has provided significant funding for malaria vaccine research and development, including support for the development of the Mosquirix vaccine.

Increasing Investments

Increasing investment in developing and improvising healthcare infrastructure is another important driver of the growth of the global malaria vaccine market. The development of effective malaria vaccines is only one part of the solution to combating this disease. Equally important is the establishment of a strong healthcare infrastructure that can effectively deliver vaccines to those who need them. In many low- and middle-income countries where malaria is most prevalent, healthcare infrastructure is often inadequate or nonexistent, making it difficult to effectively deliver vaccines and other essential healthcare services. Increasing investment in healthcare infrastructure can help to address this problem by improving the availability and accessibility of healthcare services, including vaccines. This includes investment in healthcare facilities, medical equipment, healthcare personnel, and healthcare logistics. For instance, investment in the construction of new healthcare facilities, such as clinics and hospitals, can help to expand access to healthcare services in underserved areas. Investment in medical equipment, such as refrigerators and freezers, can help to ensure that vaccines are stored properly and remain effective. Increased investment in healthcare infrastructure has been supported by both government and private sector funding. Increasing investment in healthcare infrastructure is driving the growth of the global malaria vaccine market by improving the availability and accessibility of healthcare services, including vaccines.

Recent Developments:

The malaria vaccine, known as R21/Matrix-M, which is manufactured by the Serum Institute of India, has received clearance from the Ghanaian government to be used in the country. This marks a significant step forward in the fight against malaria, which is a major public health problem in Ghana and other sub-Saharan African countries.

Mosquirix is a vaccine that is designed to provide protection against Plasmodium falciparum, the deadliest species of malaria parasite. The vaccine was developed by GlaxoSmithKline (GSK) in partnership with the PATH Malaria Vaccine Initiative, and it has been approved for use by the European Medicines Agency (EMA).

CVac is a whole-parasite malaria vaccine that uses genetically modified parasites to stimulate an immune response. In 2021, Novartis announced that it had completed a Phase 1 clinical trial of the CVac vaccine, which showed that the vaccine was safe and well-tolerated in healthy volunteers. The company plans to move forward with Phase 2 clinical trials to evaluate the efficacy of the vaccine.

In 2021, Serum Institute of India announced that it had partnered with the University of Oxford to develop a new mRNA-based malaria vaccine. The vaccine will use the same technology that was used to develop the Pfizer-BioNTech and Moderna COVID-19 vaccines. The mRNA vaccine has the potential to provide a more effective immune response compared to traditional vaccines.

Market Segmentation:

Global Malaria Vaccine Market can be segmented by vaccine type, by route of administration, and by region. Based on vaccine type, global malaria vaccine market can be divided into Pre-Erythrocytic, Erythrocytic, Multi-antigen, and Others. Based on route of administration, the global malaria vaccine market is divided into Intramuscular, Subcutaneous, Intradermal, and Others. Regionally, the Malaria Vaccine Market can be categorized into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

Market Players

GlaxoSmithKline, Plc., Novartis AG, Takeda Pharmaceutical Company, Sanaria Inc., Merck & Co., Johnson & Johnson, Pfizer Inc., Serum Institute of India Private Limited, Bharat Biotech International Limited, Moderna Inc are some of the leading players operating in the Global Malaria Vaccine Market.

Report Scope:

In this report, Global Malaria Vaccine Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global Malaria Vaccine Market, By Vaccine Type:

Pre-Erythrocytic

Erythrocytic

Multi-antigen

Others

Global Malaria Vaccine Market, By Route of Administration:

Intramuscular

Subcutaneous

Intradermal

Others

Global Malaria Vaccine Market, By Region:

North America

United States

Canada

Mexico

Europe

Germany

United Kingdom

France

Italy

Spain

Asia Pacific

India

Japan

South Korea

Australia

Vietnam

Indonesia

Myanmar

South America

Brazil

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Egypt

Turkey

Nigeria

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Malaria Vaccine Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Malaria Vaccine Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Vaccine Type (Pre-Erythrocytic, Erythrocytic, Multi-antigen, Others)
- 5.2.2. By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2022)
5.3. Product Map
- 5.3.1. By Vaccine Type
- 5.3.2. By Route of Administration
- 5.3.3. By Region

6. North America Malaria Vaccine Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Vaccine Type
- 6.2.2. By Route of Administration
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Malaria Vaccine Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Vaccine Type
    - 6.3.1.2.2. By Route of Administration
- 6.3.2. Canada Malaria Vaccine Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Vaccine Type
    - 6.3.2.2.2. By Route of Administration
- 6.3.3. Mexico Malaria Vaccine Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Vaccine Type
    - 6.3.3.2.2. By Route of Administration

7. Europe Malaria Vaccine Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Vaccine Type
- 7.2.2. By Route of Administration
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Malaria Vaccine Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Vaccine Type
    - 7.3.1.2.2. By Route of Administration
- 7.3.2. Germany Malaria Vaccine Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Vaccine Type
    - 7.3.2.2.2. By Route of Administration
- 7.3.3. United Kingdom Malaria Vaccine Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecasty
    - 7.3.3.2.1. By Vaccine Type
    - 7.3.3.2.2. By Route of Administration
- 7.3.4. Italy Malaria Vaccine Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Vaccine Type
    - 7.3.4.2.2. By Route of Administration
- 7.3.5. Spain Malaria Vaccine Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Vaccine Type
    - 7.3.5.2.2. By Route of Administration

8. Asia-Pacific Malaria Vaccine Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Vaccine Type
- 8.2.2. By Route of Administration
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. India Malaria Vaccine Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Vaccine Type
    - 8.3.1.2.2. By Route of Administration
- 8.3.2. Japan Malaria Vaccine Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Vaccine Type
    - 8.3.2.2.2. By Route of Administration
- 8.3.3. South Korea Malaria Vaccine Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Vaccine Type
    - 8.3.3.2.2. By Route of Administration
- 8.3.4. Australia Malaria Vaccine Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Vaccine Type
    - 8.3.4.2.2. By Route of Administration
- 8.3.5. Indonesia Malaria Vaccine Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Vaccine Type
    - 8.3.5.2.2. By Route of Administration
- 8.3.6. Vietnam Malaria Vaccine Market Outlook
  - 8.3.6.1. Market Size & Forecast
    - 8.3.6.1.1. By Value
  - 8.3.6.2. Market Share & Forecast
    - 8.3.6.2.1. By Vaccine Type
    - 8.3.6.2.2. By Route of Administration
- 8.3.7. Myanmar Malaria Vaccine Market Outlook
  - 8.3.7.1. Market Size & Forecast
    - 8.3.7.1.1. By Value
  - 8.3.7.2. Market Share & Forecast
    - 8.3.7.2.1. By Vaccine Type
    - 8.3.7.2.2. By Route of Administration

9. South America Malaria Vaccine Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Vaccine Type
- 9.2.2. By Route of Administration
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Malaria Vaccine Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Vaccine Type
    - 9.3.1.2.2. By Route of Administration
- 9.3.2. Colombia Malaria Vaccine Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Vaccine Type
    - 9.3.2.2.2. By Route of Administration

10. Middle East and Africa Malaria Vaccine Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Vaccine Type
- 10.2.2. By Route of Administration
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Malaria Vaccine Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Vaccine Type
    - 10.3.1.2.2. By Route of Administration
- 10.3.2. Saudi Arabia Malaria Vaccine Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Vaccine Type
    - 10.3.2.2.2. By Route of Administration
- 10.3.3. UAE Malaria Vaccine Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Vaccine Type
    - 10.3.3.2.2. By Route of Administration
- 10.3.4. Egypt Malaria Vaccine Market Outlook
  - 10.3.4.1. Market Size & Forecast
    - 10.3.4.1.1. By Value
  - 10.3.4.2. Market Share & Forecast
    - 10.3.4.2.1. By Vaccine Type
    - 10.3.4.2.2. By Route of Administration
- 10.3.5. Turkey Malaria Vaccine Market Outlook
  - 10.3.5.1. Market Size & Forecast
    - 10.3.5.1.1. By Value
  - 10.3.5.2. Market Share & Forecast
    - 10.3.5.2.1. By Vaccine Type
    - 10.3.5.2.2. By Route of Administration
- 10.3.6. Nigeria Malaria Vaccine Market Outlook
  - 10.3.6.1. Market Size & Forecast
    - 10.3.6.1.1. By Value
  - 10.3.6.2. Market Share & Forecast
    - 10.3.6.2.1. By Vaccine Type
    - 10.3.6.2.2. By Route of Administration

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches

13. Global Malaria Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Business Overview
15.2. Product Offerings
15.3. Recent Developments
15.4. Key Personnel
15.5. SWOT Analysis
- 15.5.1. GlaxoSmithKline, Plc.
- 15.5.2. Novartis AG
- 15.5.3. Takeda Pharmaceutical Company
- 15.5.4. Sanaria Inc.
- 15.5.5. Merck & Co.
- 15.5.6. Johnson & Johnson
- 15.5.7. Pfizer Inc.
- 15.5.8. Serum Institute of India Private Limited
- 15.5.9. Bharat Biotech International Limited
- 15.5.10. Moderna Inc